Antal, Sanra S.
HRN: 22-78-42 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/22/2023
CO-AMOXICLAV 625MG (TAB)
04/22/2023
04/29/2023
PO
625mg
BID X 7 Days
2nd Degree Perineal Laceration And Repair
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes